Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral...

Related Keywords

United States ,Rosalia Scampoli ,Katie Mcmanus ,Exchange Commission ,Prnewswire Trevi Therapeutics Inc ,Nasdaq ,Trevi Therapeutics Inc ,Jennifer Good ,Prurigo Nodularis ,Worst Itch Numerical Rating Scale ,Prurigo Activity Score ,Stifel Biotech Executive Summer ,Annual Global Investment ,Trevi Therapeutics ,New Haven ,Fast Track ,Private Securities Litigation Reform Act ,Operations Data ,Nc ,